Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 1316Triple Negative Breast Neoplasms 233Ovarian Neoplasms 115Carcinoma, Non-Small-Cell Lung 89Colorectal Neoplasms 86Neoplasm Metastasis 83Prostatic Neoplasms 79Neoplasms 76Lung Neoplasms 70Melanoma 57Pancreatic Neoplasms 54Endometrial Neoplasms 54Stomach Neoplasms 49Uterine Cervical Neoplasms 44Carcinoma, Intraductal, Noninfiltrating 41Squamous Cell Carcinoma of Head and Neck 38Colonic Neoplasms 37Head and Neck Neoplasms 33Carcinoma, Renal Cell 33Esophageal Neoplasms 27Breast Carcinoma In Situ 27Small Cell Lung Carcinoma 25Sarcoma 25Brain Neoplasms 25Urinary Bladder Neoplasms 22Anatomic Stage I Breast Cancer AJCC v8 22Carcinoma, Transitional Cell 20Advanced Breast Cancer 18Liver Neoplasms 17Gastrointestinal Neoplasms 17

Interventions

ixabepilone 1Standard of Care 1Practice Guidelines as Topic 1Epothilones 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Bilateral Breast Carcinoma × Breast × 90 days × Clear all
NCT00877500 2026-05-22

Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
116 enrolled
Breast

Bilateral Breast Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡